ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism ...
Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks Cofactor Genomics, a ...
Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback